凭借其明星产品GLP-1药物,诺和诺德在2025年第一季度继续展现了强劲的业绩增长态势。 2024年,诺和诺德的司美格鲁肽(含Ozempic、Wegovy、Rybelsus)仅以不到两亿美元的销售额差距,排在默沙东K药之后,与全球“药王”宝座失之交臂。2025年第一季度,司美格鲁肽全球销售额终于超过K药,暂时坐上了全球“药王”宝座。 周三(5月7日)欧股盘前,丹麦制药公司诺和诺德在官网发布了...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.